Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “hold” rating reissued by equities researchers at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. NBIX has been the subject of several other reports. Barclays upped their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 […] Read this story
